Indicated in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive breast cancer. HER2 expression must be present for initiation of Perjeta (Pertuzumab) using FDA-approved test.
Mechanism of action:
Perjeta (Pertuzumab) is a humanized monoclonal antibody designed to bind to the HER2 receptor and inhibit the ability of HER2 to interact with other HER family members (HER1, HER2, HER3, and HER4) on the surface of cancer cells. The HER signaling pathway plays a role in the formation and growth of numerous cancers, and previous clinical trials of Perjeta (Pertuzumab) in a single agent setting had suggested clinical activity - including stable disease - in heavily pretreated patients with advanced ovarian and breast cancers.
Dosage and Administration:
Perjeta (Pertuzumab) is injected into a vein through an IV. You will receive this injection in a clinic or hospital setting.
Before you receive this medication, you may need to undergo a biopsy to make sure Perjeta (Pertuzumab) is the right medication to treat your cancer.
Perjeta (Pertuzumab) is usually given once every 3 weeks. Follow your doctor's instructions.
Some side effects may occur during the injection. Tell your caregiver right away if you feel weak, tired, or nauseated, or if you have a fast heartbeat, headache, fever, chills, muscle pain, or an unusual taste in your mouth.
Get emergency medical help if you have any of these signs of an allergic reaction to Perjeta (Pertuzumab): hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Perjeta (Pertuzumab) is handled and stored by a health care provider. Keep Perjeta (Pertuzumab) out of the reach of children and away from pets.
Before starting Perjeta (Pertuzumab) treatment, make sure you tell your doctor about any other medications you are taking (including prescription, over-the-counter, vitamins, herbal remedies, etc.).
Do not receive any kind of immunization or vaccination without your doctor’s approval while taking Perjeta (Pertuzumab).
Inform your health care professional if you are pregnant or may be pregnant prior to starting this treatment. Pregnancy category D (Perjeta (Pertuzumab) may be hazardous to the fetus. Women who are pregnant or become pregnant must be advised of the potential hazard to the fetus.)
Perjeta (Pertuzumab) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.